The Latest Breaking News from Pfizer

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading…

Although Pfizer underperformed the Dow Jones this year, analysts are moderately bullish on the stock’s prospects.

Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.

Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.

The Food and Drug Administration approved and granted emergency use authorization on Aug. 22, 2024, for the newest, updated version of the COVID-19 vaccine. The Centers for Disease Control and Prevention quickly endorsed the new shot to protect against severe illness.

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Citing skyrocketing COVID spread, the FDA announced in late August that it had approved Pfizer’s Comirnaty and Moderna’s Spikevax vaccines early.

Updated Covid vaccines were approved by the FDA earlier this month

FDA approves updated Covid-19 vaccines from Moderna and Pfizer/BioNTech to enhance protection against current variants and combat rising cases.

The updated COVID shots from Pfizer-BioNTech and Moderna target the current KP.2 strain of SARS-CoV-2, a descendant of the highly contagious Omicron subvariant JN.1.

Three high-yield S&P 500 stocks, Devon Energy, Verizon Communications, and Pfizer Inc., are poised to provide a balanced mix of income and growth, making them attractive options for long-term investors.